BackXORTX Therapeutics Overview

XORTX Therapeutics Other Current Liabilities

Track XORTX Therapeutics's other current liabilities ($850K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$848714.00
118.94% YoYΔ $461063.00 vs prior year quarter

Peer trimmed avg / median

Loading

XORTX Therapeutics Other Current Liabilities History

Loading

XORTX Therapeutics vs. peers: Other Current Liabilities Comparison

Loading

XORTX Therapeutics Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

XORTX Therapeutics (XRTX) FAQ

As of the most recent data (March 2026), XRTX shows a other current liabilities of $850K. That compares with $390K in the prior-year period — up 118.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, XRTX's other current liabilities is now $850K (was $390K) — a 118.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether XORTX Therapeutics is outperforming or lagging.

Tracking XRTX's other current liabilities over time shows whether XORTX Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $850K That compares with $390K in the prior-year period — up 118.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has XORTX Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $850K) with ownership activity and broader fundamentals.

XORTX Therapeutics's other current liabilities is $850K; compare it with other Materials names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.